{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:02:52Z","timestamp":1782741772562,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00482-024-00810-4","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T17:01:49Z","timestamp":1714496509000},"page":"283-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Medikament\u00f6se Therapie der Trigeminusneuralgie","Trigeminal neuralgia: drug therapy"],"prefix":"10.1007","volume":"38","author":[{"given":"Ruth","family":"Ruscheweyh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Gierthm\u00fchlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis M.","family":"Hedderich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Go\u00dfrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"810_CR1","unstructured":"Go\u00dfrau G, Gierthm\u00fchlen J (2023) Diagnose und Therapie der Trigeminusneuralgie. S1-Leitlinie, In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. www.dgn.org\/leitlinien (abgerufen am 17. Jan. 2024)"},{"key":"810_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/ene.13950","volume":"26","author":"L Bendtsen","year":"2019","unstructured":"Bendtsen\u00a0L, Zakrzewska\u00a0JM, Abbott\u00a0J et\u00a0al (2019) European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol 26:831\u2013849. https:\/\/doi.org\/10.1111\/ene.13950","journal-title":"Eur J Neurol"},{"key":"810_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/practneurol-2020-002782","volume":"21","author":"G Lambru","year":"2021","unstructured":"Lambru\u00a0G, Zakrzewska\u00a0J, Matharu\u00a0M (2021) Trigeminal neuralgia: a\u00a0practical guide. Pract Neurol 21:392\u2013402. https:\/\/doi.org\/10.1136\/practneurol-2020-002782","journal-title":"Pract Neurol"},{"key":"810_CR4","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s40265-018-0964-9","volume":"78","author":"G Di Stefano","year":"2018","unstructured":"Di Stefano\u00a0G, Truini\u00a0A, Cruccu\u00a0G (2018) Current and Innovative Pharmacological Options to Treat Typical and Atypical Trigeminal Neuralgia. Drugs 78:1433\u20131442. https:\/\/doi.org\/10.1007\/s40265-018-0964-9","journal-title":"Drugs"},{"key":"810_CR5","doi-asserted-by":"publisher","unstructured":"Zakrzewska JM, Patsalos PN (1992) Drugs used in the management of trigeminal neuralgia. Oral Surg Oral Med Oral Pathol 74:439\u2013450. https:\/\/doi.org\/10.1016\/0030-4220(92)90292-x","DOI":"10.1016\/0030-4220(92)90292-x"},{"key":"810_CR6","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/ejp.1727","volume":"25","author":"G Di Stefano","year":"2021","unstructured":"Di Stefano\u00a0G, De Stefano\u00a0G, Leone\u00a0C et\u00a0al (2021) Real-world effectiveness and tolerability of carbamazepine and oxcarbazepine in 354 patients with trigeminal neuralgia. Eur J Pain 25:1064\u20131071. https:\/\/doi.org\/10.1002\/ejp.1727","journal-title":"Eur J Pain"},{"key":"810_CR7","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1111\/head.13963","volume":"60","author":"S Schnell","year":"2020","unstructured":"Schnell\u00a0S, Marrodan\u00a0M, Acosta\u00a0JN et\u00a0al (2020) Trigeminal Neuralgia Crisis\u2014Intravenous Phenytoin as Acute Rescue Treatment. Headache 60:2247\u20132253. https:\/\/doi.org\/10.1111\/head.13963","journal-title":"Headache"},{"key":"810_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/03331024221092435","volume":"42","author":"A Mu\u00f1oz-Vendrell","year":"2022","unstructured":"Mu\u00f1oz-Vendrell\u00a0A, Teixidor\u00a0S, Sala-Padr\u00f3\u00a0J et\u00a0al (2022) Intravenous lacosamide and phenytoin for the treatment of acute exacerbations of trigeminal neuralgia: A\u00a0retrospective analysis of 144 cases. Cephalalgia 42:1031\u20131038. https:\/\/doi.org\/10.1177\/03331024221092435","journal-title":"Cephalalgia"},{"key":"810_CR9","doi-asserted-by":"publisher","unstructured":"Zakrzewska JM, Chaudhry Z, Nurmikko TJ, et\u00a0al (1997) Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a\u00a0double-blind placebo controlled crossover trial. Pain 73:223\u2013230. https:\/\/doi.org\/10.1016\/S0304-3959(97)00104-8","DOI":"10.1016\/S0304-3959(97)00104-8"},{"key":"810_CR10","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/papr.12406","volume":"16","author":"M Yuan","year":"2016","unstructured":"Yuan\u00a0M, Zhou\u00a0H\u2011Y, Xiao\u00a0Z\u2011L et\u00a0al (2016) Efficacy and Safety of Gabapentin vs. Carbamazepine in the Treatment of Trigeminal Neuralgia: A\u00a0Meta-Analysis. Pain Pract 16:1083\u20131091. https:\/\/doi.org\/10.1111\/papr.12406","journal-title":"Pain Pract"},{"key":"810_CR11","volume-title":"Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen, S2k-Leitlinie","author":"T Schlereth","year":"2019","unstructured":"Schlereth\u00a0T (2019) Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen, S2k-Leitlinie. Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. https:\/\/dgn.org\/leitlinie\/diagnose-und-nicht-interventionelle-therapie-neuropathischer-schmerzen (Abgerufen 18.03.2024)"},{"key":"810_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/ana.410150306","volume":"15","author":"GH Fromm","year":"1984","unstructured":"Fromm\u00a0GH, Terrence\u00a0CF, Chattha\u00a0AS (1984) Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol 15:240\u2013244. https:\/\/doi.org\/10.1002\/ana.410150306","journal-title":"Ann Neurol"},{"key":"810_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s10194-016-0651-8","volume":"17","author":"ME Morra","year":"2016","unstructured":"Morra\u00a0ME, Elgebaly\u00a0A, Elmaraezy\u00a0A et\u00a0al (2016) Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a\u00a0systematic review and meta-analysis of randomized controlled trials. J\u00a0Headache Pain 17:63. https:\/\/doi.org\/10.1186\/s10194-016-0651-8","journal-title":"J Headache Pain"},{"key":"810_CR14","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/pme.12349","volume":"15","author":"Y Niki","year":"2014","unstructured":"Niki\u00a0Y, Kanai\u00a0A, Hoshi\u00a0K, Okamoto\u00a0H (2014) Immediate analgesic effect of 8\u202f% lidocaine applied to the oral mucosa in patients with trigeminal neuralgia. Pain Med 15:826\u2013831. https:\/\/doi.org\/10.1111\/pme.12349","journal-title":"Pain Med"},{"key":"810_CR15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00482-005-0460-5","volume":"20","author":"F Elsner","year":"2006","unstructured":"Elsner\u00a0F, Radbruch\u00a0L, Gaertner\u00a0J et\u00a0al (2006) Efficacy of opioid analgesia at the superior cervical ganglion in neuropathic head and facial pain. Schmerz 20:268\u2013272","journal-title":"Schmerz"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-024-00810-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00482-024-00810-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-024-00810-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T07:06:19Z","timestamp":1721372779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00482-024-00810-4"}},"subtitle":["Die neue Leitlinie","The new German guideline"],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1007\/s00482-024-00810-4","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"6 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>R.\u00a0Ruscheweyh<\/b>: A. Finanzielle Interessen: Unterst\u00fctzung durch den Innovationsfonds zur Erstellung eines Vollantrags auf dem Gebiet der \u201eneuen Versorgungsformen\u201c. \u2013\u00a0In den letzten 3\u00a0Jahren Honorare f\u00fcr Vortr\u00e4ge oder Advisory Boards sowie Unterst\u00fctzung f\u00fcr Kongressreisen von Novartis, Lilly, Lundbeck, Pfizer und Teva.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellte Assistenz\u00e4rztin in der Neurologischen Klinik und Poliklinik, Klinikum der LMU M\u00fcnchen; Angestellte bei der Deutschen Migr\u00e4ne- und Kopfschmerzgesellschaft (DMKG; Leiterin des Kopfschmerzregisters der DMKG). <b>J.\u00a0Gierthm\u00fchlen<\/b>: A. Finanzielle Interessen: Vortragst\u00e4tigkeiten f\u00fcr Weiterbildungsveranstaltungen, die von Lilly GmbH; Novartis; AbbVie; Lundbeck; Insignia; MediSage und Teva organisiert wurden. Reisekostenunterst\u00fctzung von Novartis; Gr\u00fcnenthal; Teva; Lilly GmbH. \u2013\u00a0Beratungshonorare: Omega Pharma.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellte \u00c4rztin am Universit\u00e4tsklinikum Schleswig-Holstein, Campus Kiel, Ober\u00e4rztin Interdisziplin\u00e4re Schmerz- und Palliativambulanz, Akutschmerzdienst. Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Neurologie (DGN); Deutsche Gesellschaft f\u00fcr An\u00e4sthesiologie und Intensivmedizin (DGAI); Deutsche Schmerzgesellschaft (DGSS); International Association for the Study of Pain (IASP); Complex Regional Pain Syndrome Special Interest Group (CRPS-SIG); Neuropathic Pain Special Interest Group (NeuPSIG); Deutscher Forschungsverbund Neuropathischer Schmerz (DFNS); Deutsche Migr\u00e4ne- und Kopfschmerzgesellschaft e.\u202fV. (DMKG), Pr\u00e4sident:in der CRPS-SIG (geteilt mit Janet Bultitude). <b>D.M.\u00a0Hedderich<\/b>: A. Finanzielle Interessen: D.\u00a0Hedderich gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013\u00a0B. Nichtfinanzielle Interessen: Angestellter Oberarzt, Neuroradiologie, Klinikum rechts der Isar, M\u00fcnchen, TU M\u00fcnchen. <b>G.\u00a0Go\u00dfrau<\/b>: A. Finanzielle Interessen: Forschungsf\u00f6rderung (Novartis).\u00a0\u2013 In den letzten 3\u00a0Jahren Honorare f\u00fcr Vortr\u00e4ge oder Advisory Boards sowie Unterst\u00fctzung f\u00fcr Kongressreisen von Novartis; Lilly; Lundbeck; Teva. \u2013\u00a0B. Nichtfinanzielle Interessen: Ober\u00e4rztin Neurologie und Schmerztherapie im Interdisziplin\u00e4ren Universit\u00e4tsSchmerzCentrum des Universit\u00e4tsklinikums Dresden, TU Dresden; Generalsekret\u00e4rin der DMKG. Mitgliedschaften: DMKG, DGN, DGSS, IHS, IASAT. <b>S.\u00a0Leis<\/b>: A. Finanzielle Interessen: Drittmittel: Eli Lilly und Biohaven\/Pfizer, \u201eprincipal investigator\u201c (PI); PMU Salzburg, Research and Innovation Fund.\u00a0\u2013 Vortragshonorare: Arbeitsgemeinschaft Neurologie Salzburg Innergebirg (ANSIG); Eli Lilly; Klinikum F\u00fcrth; Menarini; Neuraxpharm; Novartis; \u00d6sterreichische Gesellschaft f\u00fcr Neurologie (\u00d6GN); \u00d6sterreichische Schmerzgesellschaft (\u00d6SG); AbbVie; Pfizer; Medizin Akademie Organisationsteam. \u2013 Kostenerstattung f\u00fcr Kongressteilnahme: Fortbildungsfonds  Uniklinikum Salzburg; Merz; Teva ratiopharm. \u2013\u00a0Advisory Boards\/Expertenmeetings: Allergan; Gr\u00fcnenthal; Eli Lilly; Lundbeck; Merck; Novartis; Pfizer; Springer Verlag; Stada; Teva ratiopharm.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellt als leitender Oberarzt, Universit\u00e4tsklinik f\u00fcr Neurologie, PMU Salzburg, Mitgliedschaften: Deutsche Schmerzgesellschaft (DGSS); European Academy of Neurology (EAN), Member of the Scientific Panel Pain; \u00d6GN; \u00d6sterreichische Kopfschmerzgesellschaft (\u00d6KSG), Vizepr\u00e4sident; \u00d6SG, Vorstandsmitglied.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}